Bendamustine/Polatuzumab-vedotin/RituximabLack of efficacy

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2024年 / 2009卷 / 1期

关键词：

D O I：

10.1007/s40278-024-59369-0

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：113 / 113

相关论文

共 50 条

[1] Bendamustine/polatuzumab-vedotin/rituximabLack of efficacy following an off-label use: case report
[J]. Reactions Weekly, 2022, 1935 (1) : 113 - 113
[2] Bendamustine/polatuzumab-vedotin/rituximabCytokine release syndrome
[J]. Reactions Weekly, 2024, 1998 (1) : 114 - 114
[3] Ibrutinib/polatuzumab-vedotin/rituximabLack of efficacy and toxic epidermal necrolysis: case report
[J]. Reactions Weekly, 2022, 1929 (1) : 332 - 332
[4] Bendamustine/polatuzumab-vedotin/rituximabPeripheral neuropathy and lack of efficacy: 4 case reports
[J]. Reactions Weekly, 2022, 1921 (1) : 64 - 64
[5] Bendamustine/polatuzumab-vedotin/rituximabVarious toxicities: 5 case reports
[J]. Reactions Weekly, 2022, 1889 (1) : 84 - 84
[6] Bendamustine/polatuzumab-vedotin/rituximabVarious toxicities: 3 case reports
[J]. Reactions Weekly, 2022, 1893 (1) : 73 - 73
[7] Polatuzumab-vedotin/RituximabHaemophagocytic syndrome
[J]. Reactions Weekly, 2024, 1993 (1) : 145 - 145
[8] Bendamustine/polatuzumab-vedotin/rituximabVarious toxicities and compassionate use: 7 case reports
[J]. Reactions Weekly, 2022, 1927 (1) : 130 - 130
[9] Molecular determinants of sensitivity to Polatuzumab-Vedotin
Corcoran, Sean R.
Choi, Jaewoo
Fenner, Rachel E.
Yu, Xin
Scheich, Sebastian
Schevchenko, Galina
Papachristou, Evangelia K.
Morris, Vivian M.
Kishore, Kamal
D'Santos, Clive S.
Pittaluga, Stefania
Wright, George
Muppidi, Jagan
Hodson, Daniel J.
Staudt, Louis M.
[J]. MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
[10] Bendamustine/polatuzumab-vedotin/rituximabMucormycosis and severe COVID-19: 2 case reports
[J]. Reactions Weekly, 2023, 1941 (1) : 100 - 100

← 1 2 3 4 5 →